Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0004 | 0 | 0.5 |
Onchocerca volvulus | Vesicular acetylcholine transporter homolog | 0.0863 | 1 | 1 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0004 | 0 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.0012 | 0.0093 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0012 | 0.0093 | 0.0093 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0004 | 0 | 0.5 |
Trypanosoma brucei | mitochondrial RNA binding complex 1 subunit | 0.0004 | 0 | 0.5 |
Onchocerca volvulus | 0.0012 | 0.0093 | 0.0093 | |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0012 | 0.0093 | 1 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0012 | 0.0093 | 0.0093 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0012 | 0.0093 | 0.0093 |
Schistosoma mansoni | hypothetical protein | 0.0012 | 0.0093 | 0.0093 |
Leishmania major | hypothetical protein, conserved | 0.0004 | 0 | 0.5 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0004 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0004 | 0 | 0.5 |
Echinococcus granulosus | vesicular acetylcholine transporter | 0.0863 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0004 | 0 | 0.5 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0012 | 0.0093 | 0.0093 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0012 | 0.0093 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0012 | 0.0093 | 0.0093 |
Leishmania major | hypothetical protein, conserved | 0.0004 | 0 | 0.5 |
Echinococcus multilocularis | vesicular acetylcholine transporter | 0.0863 | 1 | 1 |
Loa Loa (eye worm) | brahma associated protein | 0.0012 | 0.0093 | 0.0093 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0012 | 0.0093 | 0.5 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0012 | 0.0093 | 0.0093 |
Leishmania major | hypothetical protein, conserved | 0.0004 | 0 | 0.5 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0004 | 0 | 0.5 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0004 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0.0093 | 0.5 |
Trypanosoma brucei | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0004 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0004 | 0 | 0.5 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0004 | 0 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0012 | 0.0093 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0012 | 0.0093 | 0.0093 |
Brugia malayi | brahma associated protein 60 kDa | 0.0012 | 0.0093 | 0.0093 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0004 | 0 | 0.5 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0012 | 0.0093 | 0.0093 |
Schistosoma mansoni | vesicular acetylcholine transporter | 0.0863 | 1 | 1 |
Loa Loa (eye worm) | vesicular acetylcholine transporter unc-17 | 0.0863 | 1 | 1 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0012 | 0.0093 | 1 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0004 | 0 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0012 | 0.0093 | 0.0093 |
Schistosoma mansoni | brg-1 associated factor | 0.0012 | 0.0093 | 0.0093 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0004 | 0 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0012 | 0.0093 | 0.5 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0012 | 0.0093 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0004 | 0 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.0012 | 0.0093 | 0.0093 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0012 | 0.0093 | 0.0093 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.